as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹2,098.7
Change
+5.3 (0.25%)
Open
₹2,093.4
Prev. Close
₹2,093.4
Day High
₹2,117.9
Day Low
₹2,065.7
Volume Analysis
Traded
10,464
Delivered
5,385
Delivery %
51.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (19.3%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,174.7 | ₹2,146.3 | ₹2,122.5 | ₹2,094.1 | ₹2,070.3 | ₹2,041.9 | ₹2,018.1 |
| Fibonacci | ₹2,146.3 | ₹2,126.36 | ₹2,114.04 | ₹2,094.1 | ₹2,074.16 | ₹2,061.84 | ₹2,041.9 |
| Camarilla | ₹2,113.06 | ₹2,108.27 | ₹2,103.49 | ₹2,094.1 | ₹2,093.92 | ₹2,089.13 | ₹2,084.35 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+35.8%
1 Week
+1.16%
1 Month
-4.65%
3 Months
-3.94%
6 Months
+65.24%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹471.05
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
17.68%
Net margin 11.22% × asset turnover 0.78x × equity multiplier 2.02x
Company Overview
Sector
Healthcare
Market Cap
₹2,262 Cr
P/E (TTM)
49.6
ROE
18.8%
Book Value
₹241.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 28 Sep 2026. Not investment advice.
TopFund Analysis
Beta Drugs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Growth (87/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%); promoter holding is falling. Strong 3-year revenue growth (19.3%).
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 8.45 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Promoter holding has decreased over last quarter: -5.53%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Beta Drugs secured Azerbaijan approvals for oncology portfolio; 15 dossiers filed, 15 more due next month.
Beta Drugs will join Valorem CXO virtual meet on 17 September 2026 at 4:00 pm IST.
Beta Drugs published newspaper notice for 21st AGM on 30 September 2026.
Beta Drugs schedules 21st AGM on 30 Sep 2026; seeks auditor reappointment and Ashutosh Shukla's reappointment.
Book closure from 24–30 September 2026 for Beta Drugs' 21st AGM on 30 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 88 | 94 | 100 | 103 | 87 | 94 | 126 |
| Expenses + | 70 | 76 | 81 | 82 | 70 | 76 | 98 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 |
| OPM % | 21.0% | 18.0% | 20.0% | 21.0% | 19.0% | 19.0% | 22.0% |
| Other Income + | -1 | 2 | 3 | 3 | 2 | 3 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 |
| Tax % | 25.0% | 26.0% | 25.0% | 26.0% | 19.0% | 24.0% | 25.0% |
| Net Profit + | 9 | 9 | 12 | 12 | 9 | 9 | 16 |
| EPS in Rs | 9 | 9 | 12 | 12 | 8 | 9 | 14 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 | 410 |
| Expenses + | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 | 327 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 83 |
| OPM % | 19.0% | 18.0% | 20.0% | 21.0% | 23.0% | 23.0% | 20.0% | 21.0% | 20.0% | 20.0% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 10 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 15 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 61 |
| Tax % | 1.0% | -2.0% | 21.0% | 27.0% | 28.0% | 25.0% | 25.0% | 26.0% | 24.0% | — |
| Net Profit + | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 46 |
| EPS in Rs | 7 | 9 | 9 | 12 | 25 | 30 | 36 | 42 | 41 | 44 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 |
| Borrowings + | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 |
| Other Liabilities + | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
| Fixed Assets + | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets + | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Cash from Investing Activity + | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Cash from Financing Activity + | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 | -22 |
| CFO/OP | 181 | 1 | 47 | 75 | 69 | 44 | 52 | 48 | 49 |
| Free Cash Flow | 9 | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 32.93% | 32.92% | 32.87% | 32.25% | 31.95% | 31.95% | 32.2% | 32.11% | 32.07% | 32.07% | 32.06% | 33.65% |
| Promoters | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.9% | 64.63% | 59.1% |
| FII | 0.32% | 0.32% | 0.32% | 0.9% | 1.16% | 1.15% | 0.9% | 0.9% | 0.9% | 1.14% | 1.16% | 1.02% |
| DII | 0.02% | 0.02% | 0.06% | 0.12% | 0.16% | 0.17% | 0.17% | 0.26% | 0.29% | 1.9% | 2.15% | 6.23% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Beta Drugs Limited (this stock) | 2,262 | 49.6 | 8.46 | 18.8% |
| Windlas Biotech Limited | 2,275 | 34.2 | 4.01 | 12.2% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Venus Remedies Limited | 2,230 | 19.2 | 3.36 | 16.8% |
| Sai Parenterals Limited | 2,226 | 107.0 | — | 4.88% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
Which Mutual Funds Hold Beta Drugs Limited?
Frequently Asked Questions about Beta Drugs Limited
Beta Drugs Limited (BETA) closed at ₹2,098.7 on NSE on 25 September 2026, up 5.3 (0.25%) from the previous close.
Beta Drugs Limited trades on the NSE (National Stock Exchange of India) under the symbol BETA.
Beta Drugs Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 49.6.
Beta Drugs Limited has a dividend yield of 0.0%.
Beta Drugs Limited's 52-week high is ₹2,808.0 and its 52-week low is ₹990.0.
Beta Drugs Limited has a market capitalisation of ₹2,262 crore.
Beta Drugs Limited has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Beta Drugs Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.